Analysts Set Masimo Co. (NASDAQ:MASI) Price Target at $167.00

Masimo Co. (NASDAQ:MASI) has received an average rating of “Moderate Buy” from the seven brokerages that are covering the firm, Marketbeat Ratings reports. Two analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. The average 12-month price objective among analysts that have issued ratings on the stock in the last year is $170.67.

Several brokerages have commented on MASI. Piper Sandler increased their price target on Masimo from $165.00 to $180.00 and gave the company an “overweight” rating in a report on Wednesday, November 6th. Wells Fargo & Company raised their target price on shares of Masimo from $171.00 to $193.00 and gave the company an “overweight” rating in a research note on Wednesday. Raymond James raised shares of Masimo from a “market perform” rating to an “outperform” rating and set a $170.00 target price for the company in a research report on Wednesday, November 6th. Stifel Nicolaus reiterated a “buy” rating and issued a $190.00 price objective (up from $170.00) on shares of Masimo in a research note on Friday, November 22nd. Finally, BTIG Research upped their price target on Masimo from $166.00 to $170.00 and gave the stock a “buy” rating in a report on Monday, October 14th.

Masimo Stock Up 0.6 %

MASI stock opened at $176.14 on Friday. The firm has a market cap of $9.43 billion, a PE ratio of 121.48 and a beta of 1.01. Masimo has a 1 year low of $101.61 and a 1 year high of $178.87. The company has a fifty day simple moving average of $156.51 and a 200 day simple moving average of $132.80. The company has a current ratio of 2.01, a quick ratio of 1.11 and a debt-to-equity ratio of 0.50.

Masimo (NASDAQ:MASI) last announced its quarterly earnings results on Tuesday, November 5th. The medical equipment provider reported $0.98 earnings per share for the quarter, topping analysts’ consensus estimates of $0.84 by $0.14. The company had revenue of $504.60 million during the quarter, compared to analysts’ expectations of $502.87 million. Masimo had a return on equity of 14.98% and a net margin of 3.85%. The business’s quarterly revenue was up 5.4% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.63 earnings per share. Sell-side analysts anticipate that Masimo will post 4.03 EPS for the current fiscal year.

Hedge Funds Weigh In On Masimo

Large investors have recently added to or reduced their stakes in the company. NBC Securities Inc. grew its holdings in shares of Masimo by 47.1% during the 3rd quarter. NBC Securities Inc. now owns 228 shares of the medical equipment provider’s stock worth $30,000 after purchasing an additional 73 shares in the last quarter. GAMMA Investing LLC lifted its position in Masimo by 75.0% in the second quarter. GAMMA Investing LLC now owns 259 shares of the medical equipment provider’s stock worth $33,000 after purchasing an additional 111 shares during the period. Northwestern Mutual Wealth Management Co. boosted its stake in Masimo by 133.3% during the second quarter. Northwestern Mutual Wealth Management Co. now owns 350 shares of the medical equipment provider’s stock worth $44,000 after buying an additional 200 shares in the last quarter. HHM Wealth Advisors LLC increased its holdings in Masimo by 25.0% in the 2nd quarter. HHM Wealth Advisors LLC now owns 625 shares of the medical equipment provider’s stock valued at $79,000 after buying an additional 125 shares during the period. Finally, Fifth Third Bancorp raised its stake in shares of Masimo by 16.4% in the 2nd quarter. Fifth Third Bancorp now owns 695 shares of the medical equipment provider’s stock valued at $88,000 after buying an additional 98 shares in the last quarter. Institutional investors and hedge funds own 85.96% of the company’s stock.

Masimo Company Profile

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.